MGI Dacogen Dosing Strategy Will Consider Reimbursement, Convenience
Executive Summary
MGI Pharma is evaluating more convenient dosing strategies for its oncologic Dacogen in patients with myelodysplastic syndromes
You may also be interested in...
MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration
MGI will highlight the efficacy profile of its myelodysplastic syndromes therapy Dacogen when detailing decitabine to oncologists
MGI Dacogen Launch Plans Stress Efficacy Profile, Treatment Duration
MGI will highlight the efficacy profile of its myelodysplastic syndromes therapy Dacogen when detailing decitabine to oncologists
Pharmion Preps For MDS Competition; Vidaza Dosing Under Study
Pharmion is testing more convenient dosing schedules for its myelodysplastic syndromes drug Vidaza (azacitidine) ahead of potential market entry of competitors in the fall